A study published in JAMA found that patients obtaining GLP-1 receptor agonist prescriptions through online platforms received them in a median of one day or less, with half of all prescriptions falling between same-day and two-day turnarounds. Some compounded GLP-1 orders—4.4% of those studied—were issued in five minutes or less. That speed leaves virtually no room for the clinical review that normally happens before prescribing a drug now used by tens of millions of Americans for obesity and diabetes.

The research, titled "Online Prescribing of GLP-1 Receptor Agonists," arrives as telehealth platforms have turned into the primary distribution channel for semaglutide and tirzepatide products—drugs that started in specialty clinics but have scaled into a mass market. A five-minute prescription is not a medical consultation. It's a transaction dressed up as a clinical decision.

The business model depends on speed

Direct-to-consumer GLP-1 dispensing is built on high volume at low margins. Hims & Hers Health launched a $49 compounded version of semaglutide (marketed as Wegovy) in February, a price point that only works when hundreds of thousands of patients move through the system quickly. The JAMA data shows just how streamlined that funnel has become. Fast review windows are the feature, not the accident—the real question for investors is whether the regulatory foundation supporting this model will hold.

It hasn't stabilized yet. The FDA said in early February it would restrict GLP-1 ingredients used in non-FDA-approved compounded drugs, a category that includes products sold by Hims & Hers and other telehealth operators. Compounding exemptions exist to cover drug shortages, not to create a discount market after brand-name supply returns to normal. If the agency tightens enforcement—a significant possibility—telehealth platforms lose the compounded-GLP-1 revenue stream they've relied on since 2024, and pricing power swings back toward Novo Nordisk and Eli Lilly.

Safety data is stoking regulatory fire

KFF Health News analyzed FDA adverse-event reports and found that medication errors tied to GLP-1 drugs have risen sharply, a pattern that emerged before the JAMA study and points to the same underlying issue: oversight has not kept up with distribution. NBC News separately documented how easy it is to buy GLP-1 drugs online and the overdose risk that comes when dosing errors occur—especially when a compounding pharmacy, rather than a supervising physician, controls the dose adjustments. A review published in ScienceDirect reached a parallel conclusion: online GLP-1 sales need stronger consumer safeguards.

Reimbursement policy feeds into this tension. Reuters reported in December that a US health agency would launch a Medicare GLP-1 payment demonstration in July 2026, designed as a temporary step toward broader Medicare coverage. If Medicare beneficiaries can access branded GLP-1 drugs through an official benefit, the price and convenience advantage of compounded products sold online evaporates.

New drugs are still coming

Pharmaceutical development has continued despite the regulatory uncertainty. Eli Lilly's next-generation obesity drug produced average weight loss of 28.7% in late-stage trials, better than results for Novo Nordisk's competing drug in comparable studies. Orforglipron, an oral GLP-1 agonist, received FDA approval for weight loss in April 2026, though diabetes approval has not yet followed—a distinction that matters because insurance companies price drugs differently depending on what condition they treat. Academic conferences are now featuring presentations on how to identify "super responders," patients who lose substantially more weight than the trial average, a development that could reshape how these drugs are prescribed.

The sector is splitting into two distinct streams. One side holds branded, FDA-approved drugs moving through standard clinical trials and insurance approval channels, with newer formulations and higher-efficacy successors expanding the potential market. The other holds compounded drugs sold through speed-optimized telehealth platforms, now facing coordinated pressure from FDA enforcement actions, adverse event data, and peer-reviewed research published in leading medical journals. For anyone assessing risk in this space, the one-day median prescription time is less a trivia point than a leading indicator of where regulators are likely to focus next.